pegozafermin

Pegozafermin is a specifically engineered glycoPEGylated analog of human fibroblast growth factor 21 (FGF21), designed to recapitulate the activity profile and prolong the half-life of native FGF21. It is being developed as an investigational therapy for metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin acts by mimicking FGF21, an endogenous hormone that regulates energy expenditure, glucose metabolism, and lipid metabolism. The drug’s glycoPEGylation technology extends its half-life and enhances stability in circulation. In clinical trials, pegozafermin has demonstrated direct anti-fibrotic and anti-inflammatory effects on the liver, significant reductions in liver fat content, improvements in insulin sensitivity and glycemic control, reductions in triglycerides and other atherogenic lipids, as well as favorable safety/tolerability profiles[2][4][5][6][7].

Brand names

pegozafermin

Other names

BIO89-100BIO-89-100BIO 89-100pegozafermin